What is the current valuation of the France radiopharmaceuticals market?

As of 2024, the France radiopharmaceuticals market was valued at 0.319 USD Billion. Read More

What is the projected market valuation for the France radiopharmaceuticals market in 2035?

The market is projected to reach a valuation of 0.764 USD Billion by 2035. Read More

What is the expected CAGR for the France radiopharmaceuticals market during the forecast period 2025 - 2035?

The expected CAGR for the France radiopharmaceuticals market during the forecast period 2025 - 2035 is 8.26%. Read More

Which application segments are driving growth in the France radiopharmaceuticals market?

The oncology segment, valued at 0.12 USD Billion in 2024, is expected to grow significantly, alongside cardiology and neurology. Read More

What are the primary end-use segments in the France radiopharmaceuticals market?

Key end-use segments include hospitals, diagnostic centers, and research institutions, with hospitals valued at 0.127 USD Billion in 2024. Read More

How do the types of radiopharmaceuticals segment the market?

The market is segmented into diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals, and radioisotopes, with diagnostic radiopharmaceuticals valued at 0.127 USD Billion in 2024. Read More

What distribution channels are prevalent in the France radiopharmaceuticals market?

The market features distribution channels such as direct sales, distributors, and online sales, with direct sales valued at 0.127 USD Billion in 2024. Read More

What formulation types are available in the France radiopharmaceuticals market?

Formulation types include liquid, solid, and lyophilized, with solid formulations valued at 0.115 USD Billion in 2024. Read More

Who are the key players in the France radiopharmaceuticals market?

Key players include Novartis, GE Healthcare, Siemens Healthineers, and Bayer, among others. Read More

What trends are expected to shape the France radiopharmaceuticals market in the coming years?

Trends suggest a growing focus on oncology and cardiology applications, driven by advancements in diagnostic and therapeutic technologies. Read More

France Radiopharmaceuticals Market

ID: MRFR/Pharma/42181-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

France Radiopharmaceuticals Market Research Report By Type (Diagnostic, Therapeutic) and By Application (Neurology, Cardiology, Oncology, Others) - Growth & Industry Forecast 2025 To 2035

France Radiopharmaceuticals Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)8.26%

2024 Market Size$ 0.32 Billion

2025 Market Size$ 0.35 Billion

2035 Market Size$ 0.76 Billion

Key Players

Novartis

GE Healthcare

Siemens Healthineers

Bayer

Elekta

Lantheus Medical Imaging

Trends

Increasing Demand for Targeted Therapies
Advancements in Imaging Technologies
Regulatory Support for Innovation

Opportunities

Growing Prevalence of Cancer
Supportive Regulatory Environment
Increasing Awareness and Education

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiology
  3. 4.1.3 Neurology
  4. 4.1.4 Thyroid Imaging
  5. 4.1.5 Infection Imaging
2. 4.2 Healthcare, BY End Use (USD Billion)
  1. 4.2.1 Hospitals
  2. 4.2.2 Diagnostic Centers
  3. 4.2.3 Research Institutions
  4. 4.2.4 Pharmaceutical Companies
3. 4.3 Healthcare, BY Type (USD Billion)
  1. 4.3.1 Diagnostic Radiopharmaceuticals
  2. 4.3.2 Therapeutic Radiopharmaceuticals
  3. 4.3.3 Radioisotopes
  4. 4.3.4 Radiopharmaceutical Generators
4. 4.4 Healthcare, BY Distribution Channel (USD Billion)
  1. 4.4.1 Direct Sales
  2. 4.4.2 Distributors
  3. 4.4.3 Online Sales
5. 4.5 Healthcare, BY Formulation (USD Billion)
  1. 4.5.1 Liquid
  2. 4.5.2 Solid
  3. 4.5.3 Lyophilized
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 GE Healthcare (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Siemens Healthineers (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bayer (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Elekta (SE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Lantheus Medical Imaging (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bracco Imaging (IT)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Iba Molecular (BR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Radiopharma (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 FRANCE MARKET ANALYSIS BY APPLICATION
3. 6.3 FRANCE MARKET ANALYSIS BY END USE
4. 6.4 FRANCE MARKET ANALYSIS BY TYPE
5. 6.5 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 FRANCE MARKET ANALYSIS BY FORMULATION
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY TYPE, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY FORMULATION, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY FORMULATION, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY END USE, 2026-2035 (USD Billion)
  3. 7.2.3 BY TYPE, 2026-2035 (USD Billion)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Billion)
  5. 7.2.5 BY FORMULATION, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

France Radiopharmaceuticals Market Segmentation

France Radiopharmaceuticals Market By Application (USD Billion, 2026-2035)

Oncology
Cardiology
Neurology
Thyroid Imaging
Infection Imaging

France Radiopharmaceuticals Market By End Use (USD Billion, 2026-2035)

Hospitals
Diagnostic Centers
Research Institutions
France Radiopharmaceuticals Market Companies

France Radiopharmaceuticals Market By Type (USD Billion, 2026-2035)

Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Radioisotopes
Radiopharmaceutical Generators

France Radiopharmaceuticals Market By Distribution Channel (USD Billion, 2026-2035)

Direct Sales
Distributors
Online Sales

France Radiopharmaceuticals Market By Formulation (USD Billion, 2026-2035)

Liquid
Solid
Lyophilized

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”